Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chemotherapy Induced Peripheral Neuropathy – Pipeline Review, H2 2016’, provides an overview of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chemotherapy Induced Peripheral Neuropathy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chemotherapy Induced Peripheral Neuropathy and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chemotherapy Induced Peripheral Neuropathy

The report reviews pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chemotherapy Induced Peripheral Neuropathy therapeutics and enlists all their major and minor projects

The report assesses Chemotherapy Induced Peripheral Neuropathy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chemotherapy Induced Peripheral Neuropathy

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Peripheral Neuropathy

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Peripheral Neuropathy pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Achelios Therapeutics, Inc.

Advinus Therapeutics Ltd

Amplyx Pharmaceuticals, Inc.

Can-Fite BioPharma Ltd.

DermaXon, LLC

Eisai Co., Ltd.

Immune Pharmaceuticals Inc.

INSYS Therapeutics, Inc.

KPI Therapeutics, Inc.

Krenitsky Pharmaceuticals Inc.

Laboratorios Del Dr. Esteve S.A.

Lpath, Inc.

MAKScientific, LLC

Metys Pharmaceuticals AG

Midatech Pharma US Inc.

Nemus Bioscience, Inc.

Neurocentrx Pharma Ltd.

Panacea Pharmaceuticals, Inc.

PeriphaGen, Inc.

PharmatrophiX, Inc.

PledPharma AB

Sova Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc.

Virobay Inc.

WEX Pharmaceuticals Inc.

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 7

List of Figures 8

Introduction 9

Global Markets Direct Report Coverage 9

Chemotherapy Induced Peripheral Neuropathy Overview 10

Therapeutics Development 11

Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Overview 11

Pipeline Products for Chemotherapy Induced Peripheral Neuropathy - Comparative Analysis 12

Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Development by Companies 13

Chemotherapy Induced Peripheral Neuropathy - Therapeutics under Investigation by Universities/Institutes 15

Chemotherapy Induced Peripheral Neuropathy - Pipeline Products Glance 16

Clinical Stage Products 16

Early Stage Products 17

Unknown Stage Products 18

Chemotherapy Induced Peripheral Neuropathy - Products under Development by Companies 19

Chemotherapy Induced Peripheral Neuropathy - Products under Investigation by Universities/Institutes 21

Chemotherapy Induced Peripheral Neuropathy - Companies Involved in Therapeutics Development 22

Achelios Therapeutics, Inc. 22

Advinus Therapeutics Ltd 23

Amplyx Pharmaceuticals, Inc. 24

Can-Fite BioPharma Ltd. 25

DermaXon, LLC 26

Eisai Co., Ltd. 27

Immune Pharmaceuticals Inc. 28

INSYS Therapeutics, Inc. 29

KPI Therapeutics, Inc. 30

Krenitsky Pharmaceuticals Inc. 31

Laboratorios Del Dr. Esteve S.A. 32

Lpath, Inc. 33

MAKScientific, LLC 34

Metys Pharmaceuticals AG 35

Midatech Pharma US Inc. 36

Nemus Bioscience, Inc. 37

Neurocentrx Pharma Ltd. 38

Panacea Pharmaceuticals, Inc. 39

PeriphaGen, Inc. 40

PharmatrophiX, Inc. 41

PledPharma AB 42

Sova Pharmaceuticals, Inc. 43

Spectrum Pharmaceuticals, Inc. 44

Virobay Inc. 45

WEX Pharmaceuticals Inc. 46

Chemotherapy Induced Peripheral Neuropathy - Therapeutics Assessment 47

Assessment by Monotherapy Products 47

Assessment by Combination Products 48

Assessment by Target 49

Assessment by Mechanism of Action 52

Assessment by Route of Administration 55

Assessment by Molecule Type 57

Drug Profiles 59

(amitriptyline + ketamine hydrochloride) - Drug Profile 59

Product Description 59

Mechanism Of Action 59

R&D Progress 59

AM-1710 - Drug Profile 63

Product Description 63

Mechanism Of Action 63

R&D Progress 63

AXPN-02 - Drug Profile 64

Product Description 64

Mechanism Of Action 64

R&D Progress 64

BR-297 - Drug Profile 65

Product Description 65

Mechanism Of Action 65

R&D Progress 65

cannabidiol - Drug Profile 66

Product Description 66

Mechanism Of Action 66

R&D Progress 66

dimiracetam - Drug Profile 69

Product Description 69

Mechanism Of Action 69

R&D Progress 69

Drugs for Peripheral Neuropathy - Drug Profile 71

Product Description 71

Mechanism Of Action 71

R&D Progress 71

DX-0332 - Drug Profile 72

Product Description 72

Mechanism Of Action 72

R&D Progress 72

E-2072 - Drug Profile 73

Product Description 73

Mechanism Of Action 73

R&D Progress 73

HM-01 - Drug Profile 74

Product Description 74

Mechanism Of Action 74

R&D Progress 74

ketoprofen - Drug Profile 75

Product Description 75

Mechanism Of Action 75

R&D Progress 75

KP-544 - Drug Profile 76

Product Description 76

Mechanism Of Action 76

R&D Progress 76

KRN-5500 - Drug Profile 77

Product Description 77

Mechanism Of Action 77

R&D Progress 77

LM11A-31BHS - Drug Profile 81

Product Description 81

Mechanism Of Action 81

R&D Progress 81

Lpathomab - Drug Profile 83

Product Description 83

Mechanism Of Action 83

R&D Progress 83

MR-309 - Drug Profile 86

Product Description 86

Mechanism Of Action 86

R&D Progress 86

NB-2111 - Drug Profile 88

Product Description 88

Mechanism Of Action 88

R&D Progress 88

NRX-2922 - Drug Profile 89

Product Description 89

Mechanism Of Action 89

R&D Progress 89

NT-24336 - Drug Profile 90

Product Description 90

Mechanism Of Action 90

R&D Progress 90

PAN-811 - Drug Profile 91

Product Description 91

Mechanism Of Action 91

R&D Progress 91

PGN-503 - Drug Profile 93

Product Description 93

Mechanism Of Action 93

R&D Progress 93

piclidenoson - Drug Profile 94

Product Description 94

Mechanism Of Action 94

R&D Progress 94

pirenzepine hydrochloride - Drug Profile 101

Product Description 101

Mechanism Of Action 101

R&D Progress 101

PP-095 - Drug Profile 102

Product Description 102

Mechanism Of Action 102

R&D Progress 102

Q-201 - Drug Profile 106

Product Description 106

Mechanism Of Action 106

R&D Progress 106

Small Molecule for Pain - Drug Profile 107

Product Description 107

Mechanism Of Action 107

R&D Progress 107

Small Molecule to Inhibit Cystathionine Gamma Lyase for Inflammatory Pain and Chemotherapy Induced Peripheral Neuropathy - Drug Profile 108

Product Description 108

Mechanism Of Action 108

R&D Progress 108

Small Molecule to Inhibit FAAH for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 109

Product Description 109

Mechanism Of Action 109

R&D Progress 109

Small Molecules to Agonize Adenosine A3 Receptor for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 110

Product Description 110

Mechanism Of Action 110

R&D Progress 110

Small Molecules to Inhibit FKBP52 for Chemotherapy Induced Peripheral Neuropathy - Drug Profile 111

Product Description 111

Mechanism Of Action 111

R&D Progress 111

Small Molecules to Inhibit Hsp90 for Amyotrophic Lateral Sclerosis and Peripheral Neuropathy - Drug Profile 112

Product Description 112

Mechanism Of Action 112

R&D Progress 112

SPI-205 - Drug Profile 113

Product Description 113

Mechanism Of Action 113

R&D Progress 113

Tetrodotoxin - Drug Profile 114

Product Description 114

Mechanism Of Action 114

R&D Progress 114

U-2902 - Drug Profile 116

Product Description 116

Mechanism Of Action 116

R&D Progress 116

VBY-036 - Drug Profile 118

Product Description 118

Mechanism Of Action 118

R&D Progress 118

XT-150 - Drug Profile 119

Product Description 119

Mechanism Of Action 119

R&D Progress 119

Chemotherapy Induced Peripheral Neuropathy - Dormant Projects 120

Chemotherapy Induced Peripheral Neuropathy - Discontinued Products 121

Chemotherapy Induced Peripheral Neuropathy - Product Development Milestones 122

Featured News & Press Releases 122

Jun 02, 2016: NEMUS Bioscience Identifies Unique Cannabidiol Derivative as a Lead Candidate in Its Neuropathy-Related Pain Management Program 122

Feb 25, 2014: DARA BioSciences' KRN5500 Receives Orphan Drug Designation From FDA 122

Jun 04, 2012: EpiCept Receives Scientific Advice From EMA For AmiKet CIPN Program 123

Apr 10, 2012: EpiCept's AmiKet Receives Fast Track Designation From FDA 124

Feb 07, 2012: EpiCept Files For AmiKet Fast Track Designation 124

Dec 23, 2011: EpiCept Receives FDA Permission To Initiate AmiKet Phase III Clinical Development 125

Appendix 127

Methodology 127

Coverage 127

Secondary Research 127

Primary Research 127

Expert Panel Validation 127

Contact Us 127

Disclaimer 128

List of Tables

List of Tables

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2016 11

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Number of Products under Development by Companies, H2 2016 (Contd..1) 14

Number of Products under Investigation by Universities/Institutes, H2 2016 15

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Development, H2 2016 17

Comparative Analysis by Unknown Stage Development, H2 2016 18

Products under Development by Companies, H2 2016 19

Products under Development by Companies, H2 2016 (Contd..1) 20

Products under Investigation by Universities/Institutes, H2 2016 21

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Achelios Therapeutics, Inc., H2 2016 22

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Advinus Therapeutics Ltd, H2 2016 23

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Amplyx Pharmaceuticals, Inc., H2 2016 24

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Can-Fite BioPharma Ltd., H2 2016 25

Chemotherapy Induced Peripheral Neuropathy – Pipeline by DermaXon, LLC, H2 2016 26

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Eisai Co., Ltd., H2 2016 27

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Immune Pharmaceuticals Inc., H2 2016 28

Chemotherapy Induced Peripheral Neuropathy – Pipeline by INSYS Therapeutics, Inc., H2 2016 29

Chemotherapy Induced Peripheral Neuropathy – Pipeline by KPI Therapeutics, Inc., H2 2016 30

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Krenitsky Pharmaceuticals Inc., H2 2016 31

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 32

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Lpath, Inc., H2 2016 33

Chemotherapy Induced Peripheral Neuropathy – Pipeline by MAKScientific, LLC, H2 2016 34

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Metys Pharmaceuticals AG, H2 2016 35

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Midatech Pharma US Inc., H2 2016 36

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Nemus Bioscience, Inc., H2 2016 37

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Neurocentrx Pharma Ltd., H2 2016 38

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Panacea Pharmaceuticals, Inc., H2 2016 39

Chemotherapy Induced Peripheral Neuropathy – Pipeline by PeriphaGen, Inc., H2 2016 40

Chemotherapy Induced Peripheral Neuropathy – Pipeline by PharmatrophiX, Inc., H2 2016 41

Chemotherapy Induced Peripheral Neuropathy – Pipeline by PledPharma AB, H2 2016 42

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Sova Pharmaceuticals, Inc., H2 2016 43

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Spectrum Pharmaceuticals, Inc., H2 2016 44

Chemotherapy Induced Peripheral Neuropathy – Pipeline by Virobay Inc., H2 2016 45

Chemotherapy Induced Peripheral Neuropathy – Pipeline by WEX Pharmaceuticals Inc., H2 2016 46

Assessment by Monotherapy Products, H2 2016 47

Assessment by Combination Products, H2 2016 48

Number of Products by Stage and Target, H2 2016 50

Number of Products by Stage and Mechanism of Action, H2 2016 53

Number of Products by Stage and Route of Administration, H2 2016 56

Number of Products by Stage and Molecule Type, H2 2016 58

Chemotherapy Induced Peripheral Neuropathy – Dormant Projects, H2 2016 120

Chemotherapy Induced Peripheral Neuropathy – Discontinued Products, H2 2016 121

List of Figures

List of Figures

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy, H2 2016 11

Number of Products under Development for Chemotherapy Induced Peripheral Neuropathy – Comparative Analysis, H2 2016 12

Number of Products under Development by Companies, H2 2016 13

Comparative Analysis by Clinical Stage Development, H2 2016 16

Comparative Analysis by Early Stage Products, H2 2016 17

Assessment by Monotherapy Products, H2 2016 47

Number of Products by Top 10 Targets, H2 2016 49

Number of Products by Stage and Top 10 Targets, H2 2016 49

Number of Products by Top 10 Mechanism of Actions, H2 2016 52

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 52

Number of Products by Routes of Administration, H2 2016 55

Number of Products by Stage and Routes of Administration, H2 2016 55

Number of Products by Molecule Types, H2 2016 57

Number of Products by Stage and Molecule Types, H2 2016 57

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports